XML 35 R21.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting
 12 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting

NOTE 14 – Segment Reporting

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the CODM in deciding how to allocate resources in assessing performance. The Company has one reportable segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and stimulation solutions (“Neuromodulation Products”). NeuroOne is a medical technology company focused on developing and commercializing Neuromodulation Products. The Company recognizes the Neuromodulation Products as one reporting segment.

 

The accounting policies of the Neuromodulation Products segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the Neuromodulation Products segment based on net loss, which is reported on the statement of operations as net loss. The measure of segment assets is reported on the balance sheet as total assets. The Company does not have any intra-entity sales or transfers.

 

The CODM uses cash forecast models in deciding how to invest into the Neuromodulation Products segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management’s compensation.

 

The statements of operations below are inclusive of the significant expense categories regularly reviewed by the CODM for the years ended September 30, 2025 and 2024:

   Years ended
September 30,		 
   2025   2024 
Product revenue  $9,097,692   $3,453,003 
Cost of product revenue   3,956,286    2,373,336 
Product gross profit   5,141,406    1,079,667 
           
Collaborations revenue   3,000,000    
—
 
           
Operating expenses:          
General and administrative   5,848,303    6,498,394 
Sales   703.570    619,276 
Marketing   832,644    784,025 
Development   4,349,834    4,483,385 
Quality assurance   633,528    581,796 
Total operating expenses   12,367,879    12,966,876 
Loss from operations   (4,226,473)   (11,887,209)
Fair value change in warrant liability   784,670    (327,092)
Financing costs   (334,063)   (228,988)
Other income, net   170,492    125,179 
Loss before income taxes   (3,605,374)   (12,318,110)
Provision for income taxes   
—
    
—
 
Net loss  $(3,605,374)  $(12,318,110)